Corvus Pharmaceuticals (CRVS) Corporate presentation summary

Strategic positioning and pipeline

• Focus on first-in-class oral immune modulators targeting ITK for broad immune disease applications, including dermatology, respiratory, GI, and rheumatology indications.

• Pipeline includes ongoing Phase 3 for PTCL, Phase 2 for atopic dermatitis (AD), and planned trials in asthma and hidradenitis suppurativa.

• Strong intellectual property protection through 2042 and experienced management team.

• Partnerships in China for clinical development and market expansion.

Mechanism of action and scientific rationale

• Soquelitinib selectively inhibits ITK, blocking Th2 and Th17 pathways, reducing inflammatory cytokines, and rebalancing immune response.

• ITK blockade increases regulatory T cells (Tregs) and decreases Th17 cells, supporting durable immune modulation.

• Modulates JAK-STAT pathway by upregulating SOCS3 and reducing JAK1 in T helper cells.

Clinical efficacy and safety in atopic dermatitis

• Phase 1 placebo-controlled trial showed dose-dependent efficacy, with up to 75% of patients achieving EASI75 and 33% achieving IGA 0/1 after 8 weeks.

• Responses maintained during drug-free follow-up, with no rebound observed post-treatment.

• Efficacy observed in patients with prior systemic therapy, including those resistant to other treatments.

• Safety profile consistent with no severe or serious adverse events; most AEs were mild and did not require dose modification.